One approach involves engineering CAR-Ms to express matrix-remodelling enzymes, such as hyaluronidase or heparanase, which facilitate the degradation of ECM components, thereby improving CAR-M infiltration into tumour tissue (Fig. 6A) [333]. This evidence concerns the gene HPSE and neoplasm.